- Dr. Rosenquist Richard
CV
Richard Rosenquist Brandell is a Professor and Senior Physician in Clinical Genetics at Karolinska Institutet and Karolinska University Hospital, Stockholm. He also serves as the Director of Genomic Medicine Sweden, a national infrastructure for implementation of precision medicine. By utilizing cutting‐edge molecular tools, his research has identified novel prognostic and predictive biomarkers in hematological malignancies, particularly chronic lymphocytic leukemia, thereby improving patient risk stratification and clinical decision-making. Additionally, he has played a key role in the adoption of clinical whole-genome/transcriptome sequencing for patients with acute leukemia. He also serves as co-chair of the newly established Precision Omics Initiative Sweden (PROMISE). Richard Rosenquist Brandell is a member of the Nobel Assembly at Karolinska Institutet.
ABSTRACT
Precision medicine is transforming healthcare by enabling personalized treatment through high-throughput sequencing and targeted therapies. While many countries have adopted national strategies, Sweden has faced challenges due to its regionally organized healthcare. To address this, key stakeholders established Genomic Medicine Sweden (GMS), a national infrastructure integrating precision diagnostic services and secure data management. GMS focuses on rare diseases, cancer, infectious diseases, pharmacogenomics, and complex diseases, while addressing informatics, ethicolegal aspects, health economics, and education. Examples highlighting successful implementation of precision medicine will be shared, along with the challenges, opportunities, and future directions in this field.